Crohns Disease Treatment Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Antibiotics, Anti-Diarrheal, Immune System Suppressants, Analgesics, Anti-Inflammatory Drugs, Monoclonal Antibodies), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) and Region Forecast 2019-2030

Crohn's Disease Treatment Market size was valued at US$ 802 million in 2023 and expected to reach US$ 1088.7 million by 2030, at a significant CAGR of 4.7% from 2024-2030. A Crohns disease belongs to a condition called inflammatory bowel disease (IBD) that causes inflammation and damage to the digestive tract. Crohns disease usually affects at the end of small intestine and beginning of colon, but inflammation may occur anywhere along the digestive tract. crohns disease may be hereditary or develop due to the malfunctioning of the immune system. Currently there is no cure for crohn's disease.

However, there are many treatments to manage disease symptoms. Inflammation, ulcers, bowel obstruction, malnutrition, colon cancer, and anal fissures are some of the complications associated with the disease. Surgery and drug therapy are some of the treatment options available to treat crohns disease. Some of the anti-inflammatory drugs used to treat crohns disease include, corticosteroids and oral 5-aminosalicylates. Global market is expected to grow at a significant rate during the forecast period. Growth in biologics development unfolded the opportunities for the new market players as they are most commonly used in crohns disease treatment. Market players are focusing on to develop new products that can treat crohns disease.

For instance, mongersen, is investigational therapy for the treatment of crohns disease, is being developed by Celgene Corporation in phase 3 clinical trials. Considering the foreseen factors market is projected to have a lucrative opportunity for market players. Manufacturers of Crohn's disease medications are concentrating on commercial distribution through retail pharmacies and online portals. Anti-inflammatory medications and corticosteroids are routinely distributed through these channels, both with and without a prescription. Consumers might also get savings when buying drugs in bulk through online platforms. The substantial rise of the anti-inflammatory medications segment of the global Crohn's disease market is mostly due to easy product availability and price cuts.

Key Developments

• On May 18, 2023: AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved RINVOQ® (upadacitinib) for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or more TNF blockers. This is the seventh FDA approval for RINVOQ across rheumatology, dermatology, and gastroenterology, where it is now indicated in both ulcerative colitis and Crohn's disease.
• On October 04, 2023: Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. announceda collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
• On Sept 14, 2022: Prometheus Laboratories Inc. announced its partnership with Takeda Pharmaceutical Company Limited ("Takeda") to nationally launch CDPATH, an innovative prognostic tool for Crohn's disease (CD) patients. CDPATH is a personalized risk assessment tool that can be used in combination with a physician's clinical assessment to evaluate an adult patient's risk for developing serious complications of CD such as bowel strictures, internal penetrating disease, or non-perianal surgery within three years.